Intelligent Pharmacy最新文献

ECLUNG consensus/guidelines development principles and methods (2024 edition)

Intelligent Pharmacy Pub Date : 2025-04-01 DOI: 10.1016/j.ipha.2024.11.004

Chunwei Xu , Yue Hao , Dong Wang , Shirong Zhang , Wenxian Wang , Qian Wang , Tangfeng Lv , Zhengbo Song , Ziming Li

引用次数: 0

Evaluation of the hypoglycemic and hypotensive efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A model-based dose–response network meta-analysis

Intelligent Pharmacy Pub Date : 2025-04-01 DOI: 10.1016/j.ipha.2025.02.001

Sanbao Chai , Fengqi Liu , Pei Li , Siyan Zhan , Feng Sun

{"title":"Evaluation of the hypoglycemic and hypotensive efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A model-based dose–response network meta-analysis","authors":"Sanbao Chai , Fengqi Liu , Pei Li , Siyan Zhan , Feng Sun","doi":"10.1016/j.ipha.2025.02.001","DOIUrl":"10.1016/j.ipha.2025.02.001","url":null,"abstract":"<div><h3>Aims</h3><div>To study the dose effect relationship of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) in reducing blood glucose and blood pressure in type 2 diabetes mellitus (T2DM).</div></div><div><h3>Materials and methods</h3><div>We searched PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov for related literature, with the search period spanning from the establishment of each platform to May 1, 2024. The main analysis method used is model-based network meta-analysis.</div></div><div><h3>Results</h3><div>A total of 192 RCTs involving <strong>67,677</strong> patients with T2DM were included in this study. The results showed that SGLT-2i reduced glycated hemoglobin A1c (HbA1c) in T2DM by 0.50 % (95 % CI: 0.49 % ∼ 0.50 %) compared with placebo. The hypoglycemic effects of Luseogliflozin and Henagliflozin on HbA1c ranked first and second, with values of 0.92 % (95 % CI: 0.61 % ∼ 1.28 %) and 0.91 % (95 % CI: 0.61 % ∼ 1.36 %), respectively. Compared with placebo, the results showed that SGLT-2i lowered systolic blood pressure (SBP) by 3.23 mmHg (95 % CI: 3.19 mmHg ∼ 3.26 mmHg) and diastolic blood pressure (DBP) by 4.16 mmHg (95 % CI: 4.13 mmHg ∼ 4.18 mmHg) in patients with T2DM, respectively. Canagliflozin showed the greatest reduction in SBP and Luseogliflozin showed the greatest reduction in DBP, respectively.</div></div><div><h3>Conclusions</h3><div>The effect of SGLT-2i in reducing HbA1c in patients with T2DM increased with increasing daily dose, with Luseogliflozin and Henagliflozin being the most effective. SGLT-2i significantly reduced both SBP and DBP in T2DM, but there was no significant dose–response relationship. Among the SGLT-2i, Canagliflozin and Luseogliflozin exhibited better antihypertensive effects.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 2","pages":"Pages 150-158"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing drug discovery with AI: Predictive modeling of pharmacokinetics using Graph Neural Networks and ensemble learning

Intelligent Pharmacy Pub Date : 2025-04-01 DOI: 10.1016/j.ipha.2024.11.002

R. Satheeskumar

{"title":"Enhancing drug discovery with AI: Predictive modeling of pharmacokinetics using Graph Neural Networks and ensemble learning","authors":"R. Satheeskumar","doi":"10.1016/j.ipha.2024.11.002","DOIUrl":"10.1016/j.ipha.2024.11.002","url":null,"abstract":"<div><div>Accurately predicting pharmacokinetic (PK) parameters such as absorption, distribution, metabolism, and excretion (ADME) is essential for optimizing drug efficacy, safety, and development timelines. Traditional experimental methods are often slow and expensive, driving the need for advanced AI-based approaches in PK modeling. This study compares cutting-edge machine learning models, including Graph Neural Networks (GNNs), Transformers, and Stacking Ensembles, against traditional models like Random Forest and XGBoost, using a dataset of over 10,000 bioactive compounds from the ChEMBL database. The Stacking Ensemble model achieved the highest accuracy (<em>R</em><sup>2</sup> of 0.92, MAE of 0.062), outperforming GNNs (<em>R</em><sup>2</sup> of 0.90) and Transformers (<em>R</em><sup>2</sup> of 0.89). These AI models excelled in capturing complex molecular interactions and long-range dependencies, significantly improving PK predictions. The high accuracy achieved (<em>R</em><sup>2</sup> = 0.92) by the Stacking Ensemble method indicates that AI models can streamline the drug discovery process by reducing costly in vivo experiments, enabling faster go/no-go decisions during preclinical evaluations, and ultimately accelerating the development of new therapeutics. This reduction in time and cost could facilitate broader industry adoption of AI-driven PK modeling. Furthermore, Bayesian optimization was employed to fine-tune hyperparameters, further enhancing the performance and robustness of these predictive models.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 2","pages":"Pages 127-140"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phytochemical profiling, FT-IR spectroscopy, and antioxidant evaluation of select Lamiaceae species

Intelligent Pharmacy Pub Date : 2025-04-01 DOI: 10.1016/j.ipha.2024.09.009

J. Joselin , B.S. Benila , T.S. Shynin Brintha , S. Jeeva

{"title":"Phytochemical profiling, FT-IR spectroscopy, and antioxidant evaluation of select Lamiaceae species","authors":"J. Joselin , B.S. Benila , T.S. Shynin Brintha , S. Jeeva","doi":"10.1016/j.ipha.2024.09.009","DOIUrl":"10.1016/j.ipha.2024.09.009","url":null,"abstract":"<div><div>The present study aimed to conduct a preliminary phytochemical analysis of aqueous, ethanol, and hexane leaf extracts from <em>Anisomeles malabarica</em> (L.) R.Br. ex Sims, <em>Leucas aspera</em> (Willd.) Link., <em>Ocimum tenuiflorum</em> L., and <em>Plectranthus amboinicus</em> (Lour.) Spreng. The analysis revealed the presence of terpenoids, saponins, glycosides, phenolics, fats, oils, tannins, quinines, and phlobatannins. Quantitative measurements showed soluble sugars at 1.92, 3.76, 2.45, and 2.07 mg/g, amino acids at 0.53, 4.74, 2.3, and 3.25 mg/g, and proteins at 5.43, 2.8, 7.32, and 4.75 mg/g, respectively. Flavonoid contents were 2.43, 6.85, 4.8, and 3.20 μg/g. Phenolic content was highest in <em>Anisomeles malabarica</em> (1.2 mg/g). Chlorophyll levels ranged from 0.4 to 2.15 mg/g, while carotenoids were highest in <em>Plectranthus amboinicus</em> (5.45 μg/g). All leaf extracts exhibited hydroxyl radical and superoxide anion scavenging activities, which increased with extract concentration. FT-IR analysis confirmed the presence of various functional groups. These findings suggest the potential of these Lamiaceae leaves in developing antibiotics and insecticides.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 2","pages":"Pages 111-117"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and validation of a UPLC-HR-SIM method to quantify semaglutide for its pharmacokinetic study

Intelligent Pharmacy Pub Date : 2025-04-01 DOI: 10.1016/j.ipha.2025.01.002

Xinyi Jiang , Tong Li , Meng Yu , Yiran Zhao , Xiangyi Wang , Yanhe Zhou , Xinmiao Guo , Jiuming He , Jianpeng Huang

{"title":"Development and validation of a UPLC-HR-SIM method to quantify semaglutide for its pharmacokinetic study","authors":"Xinyi Jiang , Tong Li , Meng Yu , Yiran Zhao , Xiangyi Wang , Yanhe Zhou , Xinmiao Guo , Jiuming He , Jianpeng Huang","doi":"10.1016/j.ipha.2025.01.002","DOIUrl":"10.1016/j.ipha.2025.01.002","url":null,"abstract":"<div><h3>Aim</h3><div>To develop a highly sensitive and interference-resistant ultra performance liquid chromatography (UPLC) coupled with high-resolution selected ion monitoring (HR-SIM) mass spectrometry method for the quantification of semaglutide in biological samples, and to apply it for pharmacokinetic analysis.</div></div><div><h3>Method</h3><div>The UPLC-HR-SIM method was utilized to quantify semaglutide in beagle plasma, requiring minimal sample pretreatment. The method demonstrated a lower limit of quantification (LLOQ) of 5.0 ng/mL for semaglutide in beagle plasma.</div></div><div><h3>Results</h3><div>Following intravenous (iv) administration at a dose of 0.030 mg/kg, the plasma concentration of semaglutide in beagles exhibited a multi-exponential decay pattern, with an average elimination half-life (t<sub>1/2</sub>) of 44.90 ± 11.45 h.</div></div><div><h3>Conclusions</h3><div>The UPLC-HR-SIM method has proven to be a highly sensitive and robust approach for the quantification of peptide-based drugs. This method will enhance the understanding of the pharmacokinetics and pharmacodynamics of semaglutide and facilitate further research into the pharmacokinetics of other peptide therapeutics.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 2","pages":"Pages 143-149"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in contemporary pharmacological innovation: Mechanistic insights and emerging trends in drug discovery and development

Intelligent Pharmacy Pub Date : 2025-04-01 DOI: 10.1016/j.ipha.2024.10.001

Sanjoy Majumder , Gagan Kumar Panigrahi

{"title":"Advancements in contemporary pharmacological innovation: Mechanistic insights and emerging trends in drug discovery and development","authors":"Sanjoy Majumder , Gagan Kumar Panigrahi","doi":"10.1016/j.ipha.2024.10.001","DOIUrl":"10.1016/j.ipha.2024.10.001","url":null,"abstract":"<div><div>Developing a new drug and bringing it to the market is a complex and time-consuming process that involves multiple phases of drug discovery and development. However, recent advancements in various technologies, such as multi-omics, genome editing, Artificial Intelligence (AI), and Machine Learning (ML), have significantly improved this process. These technologies have made the process more accurate, less time-consuming, and cost-effective compared to the conventional methods of drug discovery and development. In the current age, discovering and developing drugs is a collaborative effort that involves scientific breakthroughs, technological advancements, and regulatory oversight. The pharmaceutical industry is constantly innovating new techniques, fostering interdisciplinary collaboration, and prioritizing patient-centered approaches. In this review, we explore the latest and most updated information about using advanced technologies in drug discovery. The review begins by briefly explaining the conventional drug discovery and development process, and then delves into the applications of multi-omics, genome editing technology, systems biology, artificial intelligence, and machine learning.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 2","pages":"Pages 118-126"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A critical review on zinc oxide nanoparticles: Synthesis, properties and biomedical applications

Intelligent Pharmacy Pub Date : 2025-02-01 DOI: 10.1016/j.ipha.2024.08.004

Suddhasattya Dey , Dibya lochan Mohanty , Noota Divya , Vasudha Bakshi , Anshuman Mohanty , Deepankar Rath , Sriparni Das , Arijit Mondal , Sourav Roy , Rajarshee Sabui

{"title":"A critical review on zinc oxide nanoparticles: Synthesis, properties and biomedical applications","authors":"Suddhasattya Dey , Dibya lochan Mohanty , Noota Divya , Vasudha Bakshi , Anshuman Mohanty , Deepankar Rath , Sriparni Das , Arijit Mondal , Sourav Roy , Rajarshee Sabui","doi":"10.1016/j.ipha.2024.08.004","DOIUrl":"10.1016/j.ipha.2024.08.004","url":null,"abstract":"<div><h3>Background</h3><div>ZnO-NPs is an inorganic metal oxide that meets as medicine, a preservative in packaging, as well as an antibacterial agent without risk. The qualities of ZnO-NPs are influenced by their size, shape, concentration, and length of contact with the bacterial cell. There are many uses for ZnO including food technology, agriculture, cosmetology, optoelectronics, drug transporters, and antibacterial agents.</div></div><div><h3>Methods</h3><div>The antibacterial potential of ZnO-NPs mediated by plant extracts is superior against bacterial and fungal infections and human diseases. Trifolium, Justicia adhathoda, Physalis alkekengi L, Cassia auriculata, Pretence blossoms, Aloe barbadenis, Pongamia pinnata, Limoniaacidissima, Plectranthusamboinicus, Sedum alfredii Hance, and Aspidoterys cordata have all been discovered as excellent sources for the synthesis of NPs. ZnO-NPs is an inorganic metal oxide that meets the above-mentioned requirements, which can be utilised as medicine, a preservative in packaging, as well as an antibacterial agent without risk16. The qualities of ZnO-NPs are influenced by their size, shape, concentration, and length of contact with the bacterial cell.</div></div><div><h3>Conclusion</h3><div>It provides an overview of the numerous synthesis approaches, characterization techniques, and biomedical uses of organically generated ZnO-NPs in food, pharmaceutical and textile sectors. It has been discovered that ZnO-NPs produced by green synthesis are more useful for pharmacological and biological applications, particularly antimicrobials.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 53-70"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing monoclonal antibodies with natural products: Mechanisms and applications 用天然产品增强单克隆抗体：机制与应用

Intelligent Pharmacy Pub Date : 2025-02-01 DOI: 10.1016/j.ipha.2024.09.002

Madhan Gunasekaran , Sarvananda L , Amal D. Premarathna

{"title":"Enhancing monoclonal antibodies with natural products: Mechanisms and applications","authors":"Madhan Gunasekaran , Sarvananda L , Amal D. Premarathna","doi":"10.1016/j.ipha.2024.09.002","DOIUrl":"10.1016/j.ipha.2024.09.002","url":null,"abstract":"<div><div>Monoclonal antibodies (mAbs) have revolutionized therapeutic strategies across a broad spectrum of diseases, yet their efficacy remains constrained by challenges such as suboptimal tumor penetration and insufficient cytotoxicity. This study pioneers an integrative approach, harnessing the untapped potential of plant-derived glycosides and innovative biotechnological advances to redefine mAb efficacy. Specifically, we investigate the novel application of beta-glucan analogs engineered for enhanced immunomodulatory effects, targeting not only malignant cells but also the tumor microenvironment to optimize mAb penetration. Moreover, we introduce a groundbreaking strategy in antibody-drug conjugates (ADCs) by leveraging previously unexploited natural toxins, such as modified saporin variants, which are bioengineered to achieve selective cytotoxicity with minimal off-target effects. This novel ADC formulation is further optimized through the use of nanoencapsulation techniques, ensuring precise delivery and controlled release within the tumor milieu. The research also focuses on hybrid expression systems, scalable mAb production, nanoencapsulation for targeted delivery, and the integration of natural and synthetic techniques for improved antibody therapies. By combining plant-based expression systems with synthetic biology tools, creating a hybrid platform that surpasses traditional plant or mammalian systems in both yield and safety. This approach not only reduces production costs but also introduces a scalable method for the rapid adaptation of mAbs in response to emerging pathogens or tumor mutations. This study opens new avenues by blending natural and synthetic methodologies, ultimately enhancing the therapeutic outcomes of mAbs across various disease states. It underscores the transformative potential of integrating cutting-edge technologies with natural compounds, paving the way for more effective, targeted, and adaptable antibody-based therapies.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 84-89"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Formulation development and evaluation of floating microspheres of drotaverine hydrochloride as gastroretentive dosage form

Intelligent Pharmacy Pub Date : 2025-02-01 DOI: 10.1016/j.ipha.2024.08.002

Hritik R. Bhilare , Vishwas C. Bhagat , Pravin B. Awate , Dipak P. Kardile , Rajkumar V. Shete

{"title":"Formulation development and evaluation of floating microspheres of drotaverine hydrochloride as gastroretentive dosage form","authors":"Hritik R. Bhilare , Vishwas C. Bhagat , Pravin B. Awate , Dipak P. Kardile , Rajkumar V. Shete","doi":"10.1016/j.ipha.2024.08.002","DOIUrl":"10.1016/j.ipha.2024.08.002","url":null,"abstract":"<div><div>The aim of the current research work is to formulate and characterized the floating microspheres of drotaverine hydrochloride (DRH). DRH is an antispasmodic drug which has a short residence in the intestine during diarrhoea that prompts poor bioavailability and frequent dosing. Microspheres were prepared by solvent evaporation technique by using polymers such as ethyl cellulose and HPMC. Floating microspheres prepared by using Design-Expert® version13 software with 3<sup>2</sup> full factorial designs. Further, microspheres were evaluated for flow characteristics, entrapment efficiency, % yield, particle size analysis, % buoyancy, zeta potential analysis, scanning electron microscopy and <em>in-vitro</em> drug release. <em>In vitro</em>, drug release studies were carried out in a 0.1N HCl solution. Micromeritics studies showed good flow properties and maximum entrapment efficiency was found to be 84.83%. The microspheres were spherical in shape with distinct pores, observed under scanning electron microscopy. The in vitro buoyancy was found to be in the range of 69.23%–84.72% and a total buoyancy time of more than 10 h. Results clearly stated that DRH floating microspheres were safe and effective drug delivery over an extended period which can increase bioavailability, and patient compliance, and decrease dosing frequency.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 35-45"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring nanoformulation drug delivery of herbal actives for enhanced therapeutic efficacy: A comprehensive review 探索中草药活性成分的纳米配方给药，以提高疗效：综述

Intelligent Pharmacy Pub Date : 2025-02-01 DOI: 10.1016/j.ipha.2024.07.004

Divyanshi Sharma, Arti Gupta, Reetika Rawat, Shipra Sharma, Jitendra Singh Yadav, Anshika Saxena

{"title":"Exploring nanoformulation drug delivery of herbal actives for enhanced therapeutic efficacy: A comprehensive review","authors":"Divyanshi Sharma, Arti Gupta, Reetika Rawat, Shipra Sharma, Jitendra Singh Yadav, Anshika Saxena","doi":"10.1016/j.ipha.2024.07.004","DOIUrl":"10.1016/j.ipha.2024.07.004","url":null,"abstract":"<div><h3>Background</h3><div>In this present review we have focused on nanoformulation drug delivery approach to deliver active drug constituents. As it can minimizes the limitations associated with conventional therapies such as rapid gastric emptying, high surface area, site specific controlled drug delivery high cellular uptake, improved bioavailability, cost effectiveness, patient compliance, and improved therapeutic efficacy of drug along with reduction in systemic and local toxicity by governing the drug release behaviour.</div></div><div><h3>Purpose</h3><div>Over the years, nanoparticles have emerged as an amazing dosage form owing to their advantages such as permeability across barriers, controlled drug release and higher stability. They can be linked to specific ligands which can allow the development of targeted therapies. Hence, targeted treatments of nanoformulations for asthma and sepsis may help to maximize therapeutic benefit and helps to lower their severity.</div></div><div><h3>Conclusion</h3><div>This review highlights the nanoformulations and their potential application in drug delivery. Mechanism of action of various phytoconstituents such as flavonoids and triterpenoids is also discussed. The flavonoid as well as triterpenoid loaded nanoparticles seems to be a promising drug delivery systems, especially on account of account of its management in inflammatory diseases.</div></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"3 1","pages":"Pages 26-34"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141841903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0